Literature DB >> 17653687

[The value of imaging techniques for bone metastases].

C Kratochwil1.   

Abstract

Bone metastases are common by prostate and renal carcinomas but prostate carcinomas are predominantly osteoblastic metastases and renal carcinomas often osteolytic. Apart from bone scintigraphy and conventional X-ray imaging, computed tomography (CT), magnetic resonance tomography (MRT) and positron emission tomography (PET) can also be used for primary diagnosis. X-rays and CT are less sensitive but better for evaluating the stability of metastases. Primary diagnosis of prostate carcinomas should encompass selective bone imaging and skeletal scintigraphy is also recommended. Local recurrences or lymph node metastases can be detected using PET with (11)C-choline. MRT is the method with higher sensitivity and specificity but for whole body scans is, at present, very time-consuming and, therefore, impractical and cost-intensive. However, for selective, non-invasive valency evaluation of suspect metastases, it is considered the gold standard for the tumor entities prostate and renal carcinomas where the results of FDG PET are consistently negative.

Entities:  

Mesh:

Year:  2007        PMID: 17653687     DOI: 10.1007/s00120-007-1520-5

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  16 in total

1.  Association of prostate-specific antigen levels and patterns of benign and malignant uptake detected. on bone scintigraphy in patients with newly diagnosed prostate carcinoma.

Authors:  A F Jacobson
Journal:  Nucl Med Commun       Date:  2000-07       Impact factor: 1.690

2.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET.

Authors:  H E Daldrup-Link; C Franzius; T M Link; D Laukamp; J Sciuk; H Jürgens; O Schober; E J Rummeny
Journal:  AJR Am J Roentgenol       Date:  2001-07       Impact factor: 3.959

4.  Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET.

Authors:  Igle J de Jong; Jan Pruim; Philip H Elsinga; Willem Vaalburg; Han J Mensink
Journal:  J Nucl Med       Date:  2003-03       Impact factor: 10.057

5.  [Advancement of PET and PET/CT in prostate carcinoma].

Authors:  S N Reske; N M Blumstein; G Glatting
Journal:  Urologe A       Date:  2006-06       Impact factor: 0.639

6.  The diagnostic value of bone scan in patients with renal cell carcinoma.

Authors:  S Koga; S Tsuda; M Nishikido; Y Ogawa; K Hayashi; T Hayashi; H Kanetake
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

7.  Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography.

Authors:  H Schirrmeister; A Buck; A Guhlmann; S N Reske
Journal:  Thyroid       Date:  2001-07       Impact factor: 6.568

8.  Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase.

Authors:  L F Wymenga; J H Boomsma; K Groenier; D A Piers; H J Mensink
Journal:  BJU Int       Date:  2001-08       Impact factor: 5.588

Review 9.  [Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors].

Authors:  S Machtens; A R Boerner; M Hofmann; W H Knapp; U Jonas
Journal:  Urologe A       Date:  2004-11       Impact factor: 0.639

10.  The value of nuclear bone imaging in advanced prostatic cancer.

Authors:  J J Pollen; K Gerber; W L Ashburn; J D Schmidt
Journal:  J Urol       Date:  1981-02       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.